Nureca Q2 FY27 revenue up 55% at Rs 58.53 cr, highest in 20 quarters

Compliance View source PDF Explain this filing

NURECA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹317.10

prior close

₹328.90

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.6%+6.3% vs market

Medical Equipment & Supplies peers, median of 11sector-3.0%+6.7% vs sector

On the reaction day the stock moved 6.3 pts more than Nifty Microcap 250 and 6.7 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7-2.6+6.3-3.0+6.7

Next day

+3.5-3.6+7.1-4.7+8.2

-0.1-5.8+5.7-6.8+6.7

-2.6-5.5+2.9-5.2+2.6

-2.2pendingpending-4.3+2.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nureca reported Q2 FY27 revenue of Rs 58.53 crore, up 55% YoY, the highest in 20 quarters. Operating profit grew 60% to Rs 5.23 crore, the highest in 19 quarters. PAT rose 12% to Rs 4.05 crore, EPS at Rs 4.25. H1 FY27 revenue grew 37% to Rs 98.87 crore, PAT up 60% to Rs 7.12 crore. Growth was broad-based across e-commerce, quick-commerce and offline, with e-commerce at 88% of revenue. The company remains debt-free.

Likely market impact

Strong quarterly performance with record revenue, broad-based growth across channels and debt-free status is positive for shareholders.